Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Am J Hematol. 2017 Feb 3;92(3):238–243. doi: 10.1002/ajh.24625

Table 2. Frequency and outcomes of additional chromosomal abnormalities.

ACA Group1 N (%)2 RFS OS
Median RFS (months) 5-year RFS rate (%) Median OS (months) 5-year OS rate (%)
HeH 25 (21) 124 68 125 67
-7/7q 24 (20) 58 49 76 58
+der(22)t(9;22) 15 (16) 11 31 22 22
-9/9p 15 (16) 17 34 28 26
+21 8 (7) not reached 75 not reached 75
+8 7 (6) 70 56 53 48
Translocation of 1q21 7 (6) 38 50 not reached 63
1

Patients with more than one ACA are included in each individual ACA category. However, patients with HeH were excluded from analysis of individual ACAs.

2

Percentages represent proportion of patients with given abnormality out of evaluable population of 118 patients with ACAs

ACA, additional chromosomal abnormalities; RFS, relapse-free survival; OS, overall survival; HeH, high hyperdiploidy